Moliya
Moliya
Bosh sahifaN1BI34 • BVMF
Neurocrine Biosciences Bdr
37,36 R$
22-sen, 22:14:48 (GMT-3) · BRL · BVMF · Ogohlantirish
AksiyalarBR qimmatli qogʻoziBosh shtabi: AQSH
Yopilish kursi
37,36 R$
Yillik diapazon
25,64 R$ - 44,95 R$
Bozor kapitalizatsiyasi
14,54 mlrd USD
Oʻrtacha hajm
71,00
Narx/foyda
-
Dividend daromadliligi
-
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD)iyn, 2025Y/Y qiyosi
Daromad
687,50 mln16,49%
Joriy xarajat
286,30 mln18,31%
Sof foyda
107,50 mln65,38%
Sof foyda marjasi
15,6442,05%
Har bir ulushga tushum
1,651,23%
EBITDA
152,90 mln-1,48%
Amaldagi soliq stavkasi
32,60%
Jami aktivlari
Jami passivlari
(USD)iyn, 2025Y/Y qiyosi
Naqd pul va qisqa investitsiyalar
975,60 mln-6,09%
Jami aktivlari
3,89 mlrd17,69%
Jami passivlari
1,20 mlrd50,23%
Umumiy kapital
2,69 mlrd
Tarqatilgan aksiyalar
99,18 mln
Narxi/balansdagi bahosi
1,37
Aktivlardan daromad
9,61%
Kapitaldan daromad
11,72%
Naqd pulning sof oʻzgarishi
(USD)iyn, 2025Y/Y qiyosi
Sof foyda
107,50 mln65,38%
Operatsiyalardan naqd pul
102,00 mln57,89%
Sarmoyadan naqd pul
-29,00 mln-2,84%
Moliyadan naqd pul
-3,30 mln98,87%
Naqd pulning sof oʻzgarishi
69,90 mln127,24%
Boʻsh pul
25,20 mln126,07%
Haqida
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Tashkil etilgan
1992
Xodimlar soni
1 800
Yana
Bu sizni qiziqtirishi mumkin
Bu roʻyxat oxirgi qidiruvlar, kuzatilgan aksiyalar va boshqa faoliyatdan tuzilgan. Batafsil

Barcha axborotlar faqat maʼlumot sifatida “shundayligicha” taqdim etilgan, ulardan moliyaviy maslahat sifatida foydalanmang, ular savdo maqsadlari yoki investitsiya, soliq, yuridik, buxgalteriya yoki boshqa turdagi maslahat emas. Google investitsiya borasida maslahatchi emas, bu roʻyxatdagi kompaniyalar yoki ularning aksiyalari borasida hech qanday nuqtai nazar, tavsiya yoki fikr bildirmaydi. Har qanday savdoni boshlashdan oldin broker yoki moliyaviy vakil bilan maslahatlashib, narxlarni tekshiring. Batafsil
Qidiruv
Qidiruv maydonini tozalash
Qidiruvni yopish
Google ilovalari
Asosiy menyu